Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
May 14th, 2025
Neuren Pharmaceuticals - DAYBUE Sales Up 11%
Read More
April 28th, 2025
Neuren Confirms Endpoints for Phase III Study in PMS
Read More
March 5th, 2025
Neuren Pharmaceuticals Continues to Build Cash Balance
Read More
August 1st, 2024
Summit Coverage: Neuren Pharmaceuticals Outlines Path Forward for NNZ-2591
Read More
August 1st, 2024
Neuren Pharmaceuticals Reports Positive Results in Third Indication - Angelman Syndrome
Read More
June 13th, 2024
Neuren Pharmaceuticals: Positive Phase II Results in Second Study with NNZ-2591
Read More
January 4th, 2024
Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Neuren)
Read More
November 20th, 2023
Neuren Completes First of Four Phase II Studies
Read More
November 3rd, 2023
Neuren Pharmaceuticals – Strong DAYBUE Sales in September Quarter at US$67 million
Read More
July 21st, 2023
Neuren Pharmaceuticals Moves to Worldwide License for Trofinetide and NNZ-2591 with Acadia
Read More
March 17th, 2023
From Benchtop to the Clinic - Stunning Success for Neuren Pharmaceuticals
Read More
February 24th, 2023
Neuren Pharmaceuticals - FDA Decision on Trofinetide Approaching
Read More
August 5th, 2022
Neuren Pharmaceuticals - Partner Files Trofinetide for US Approval
Read More
Pages
1
